Sirtex: Interim result 2013

Fast-growing companies rarely rise in a straight line. Jason Prowd outlines why we're still backing Sirtex following a less than impressive interim result.

Sirtex Medical posted another record half of dose sales, which rose 31% to 3,522 for the half-year ended 31 December. This translated into revenue of $46.0m, up 25% for the period, and net profit of $7.8m, a rise of 28%. Earnings per share followed suit, rising 26% to 13.6 cents. As in the previous year, no interim dividend will be paid (although a final dividend of 10 cents was paid during the half, up from 7 cents in 2011).



{{ twilioFailed ? 'SMS Code Failed to Send…' : 'An SMS verification code has been sent ...' }}

Hi {{ user.FirstName }}

Looks like you have already taken a free trial

Please enter your payment details

We have sent you a code via SMS to {{user.DayPhone}}

please enter this code below to complete your SMS verification

We cannot send you a code via SMS to {{user.DayPhone}}

If you didn't receive SMS code please

SMS code cannot be sent due to: {{ twilioStatus }}

Please select one of the options below:

Looks you are already a member. Please enter your password to proceed

Please untick this box when using a public or shared device

Verify your mobile number to proceed...

Please check your mobile number below and press the Send Verification Code button. This will be used to complete your verification in the next step.

Please sign up for full access


Updating information

Please wait ...


{{ productPrice }} / day
( GST included )
Price $0
GST $0
Discount -{{productDiscount}}
TOTAL {{productPrice}}
  • Mastercard
  • Visa

Please click on the ACTIVATE button to finalise your membership


The email address you entered is registered with InvestSMART.

Please login or select "Don't know password"

Please untick this box when using a public or shared device

Register as a new member

(using a different email)

Related Articles